Recurrent Lung Cancer

Oncology
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alpha Tau Medical
Alpha Tau MedicalJERUSALEM, Israel
1 program
Radiation: Diffusing Alpha Radiation Emitters TherapyN/A1 trial
Active Trials
NCT05632913Recruiting10Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
Alpha Tau MedicalRadiation: Diffusing Alpha Radiation Emitters Therapy

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

NCT05632913Alpha Tau MedicalRadiation: Diffusing Alpha Radiation Emitters Therapy

Alpha Radiation Emitters Device for the Treatment of Recurrent Lung Cancer

Start: Jul 2023Est. completion: Feb 202710 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 10 patients
1 companies competing in this space